Westerkirk Capital Inc. Grows Stake in Eli Lilly and Company $LLY

Westerkirk Capital Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 21.2% during the fourth quarter, Holdings Channel reports. The fund owned 13,199 shares of the company’s stock after buying an additional 2,313 shares during the period. Eli Lilly and Company makes up approximately 1.4% of Westerkirk Capital Inc.’s portfolio, making the stock its 13th largest position. Westerkirk Capital Inc.’s holdings in Eli Lilly and Company were worth $14,185,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $25,000. Miller Global Investments LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at about $33,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Eli Lilly and Company by 342.9% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after buying an additional 24 shares in the last quarter. Dorato Capital Management purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $36,000. Finally, New England Capital Financial Advisors LLC lifted its stake in shares of Eli Lilly and Company by 142.9% during the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after buying an additional 20 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,149.38 on Tuesday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,182.73. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The stock has a market capitalization of $1.08 trillion, a PE ratio of 40.83, a P/E/G ratio of 1.24 and a beta of 0.53. The company’s 50 day simple moving average is $979.60 and its two-hundred day simple moving average is $1,013.80.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the company posted $3.34 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts predict that Eli Lilly and Company will post 35.8 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Leerink Partners set a $1,119.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, May 26th. Royal Bank Of Canada restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Bank of America upped their price target on shares of Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the company a “buy” rating in a research note on Tuesday, May 26th. Guggenheim restated a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. Finally, Daiwa Securities Group upped their price target on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly reported strong Phase 3 results for retatrutide, its next-generation obesity drug, with data showing major weight-loss benefits and improvements in obesity-related conditions such as sleep apnea and knee pain, reinforcing expectations that Lilly can extend its lead in the fast-growing weight-loss market. Article Title
• Positive Sentiment: Lilly also announced detailed Phase 3 data for Foundayo (orforglipron), its oral GLP-1 candidate, showing superior A1C control and weight loss versus oral semaglutide and supporting a planned FDA filing by the end of the second quarter. Article Title
• Positive Sentiment: Investors are also encouraged by Lilly’s broader obesity franchise momentum, including signs that its GLP-1 portfolio could expand into more patients and indications, which may support revenue growth beyond its current blockbuster drugs. Article Title
• Neutral Sentiment: The Lilly Foundation and Convatec committed about $5 million to Partners In Health to improve care for chronic conditions; this is a positive corporate-social headline, but it is unlikely to materially affect earnings or the stock. Article Title
• Neutral Sentiment: AlzeCure Pharma said it entered a collaboration and out-licensing agreement with Lilly for an Alzheimer’s project, which adds optionality to Lilly’s research pipeline but does not appear to be a near-term stock driver. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.